Dexamethasone erythrocyte-encapsulated - EryDel

Drug Profile

Dexamethasone erythrocyte-encapsulated - EryDel

Alternative Names: Dexa 21-P – EryDel; Ery-Dex

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EryDel
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ataxia telangiectasia; Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ataxia telangiectasia
  • No development reported Duchenne muscular dystrophy
  • Discontinued Chronic obstructive pulmonary disease; Crohn's disease; Cystic fibrosis; Ulcerative colitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Ataxia-telangiectasia(In volunteers) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Duchenne muscular dystrophy(In volunteers) in USA (IV, Infusion)
  • 06 Mar 2017 Phase-III clinical trials in Ataxia telangiectasia (In children, In adolescents, In adults, In the elderly) in Tunisia, India, Australia, Israel, USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top